The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Machine Learning
- Medical School
- Nano Medicine
- Parkinson's disease
- Quantum Computing
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- The Global Machine Learning Market is expected to grow by USD 11.16 bn during 2020-2024, progressing at a CAGR of 39% during the forecast period -…
- The 2021 Genesis G80 Packs ‘Machine Learning Cruise Control’ to Go With Stunning Looks – The Drive
- DMway Analytics Offers Its AUTO-ML Platform Free of Charge to Every Ministry of Health Department and Covid-19 Research Center Globally – AiThority
- Machine Learning in Finance Market Provides in-depth analysis of the Industry, with Current Trends and Future Estimations to Elucidate the Investment…
- What Researches says on Machine learning with COVID-19 – Techiexpert.com – TechiExpert.com
- what dors coronavirus recoveries mean
- what does recovered mean for the covid virus?
- what does recovered from covid-19 mean
- what does recovered from covid 19 mean
- what does mild covid look like
- covid 19 recovered meaning
- what does recovery of covid look like
- mild symptoms of covid and risk for exacerbation
- what does recovered mean covid-19
- what does a covid antibody look like
|Search Immortality Topics:|
Category Archives: Stem Cell Therapy
Global Cell Therapy Market Analysis (2019 to 2026) – Key Market Developments and Financials of the Key Players – ResearchAndMarkets.com – Yahoo…
The "Global Cell Therapy Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
The Cell Therapy market is expected to reach $9.76 billion by 2026 growing at a CAGR of 7.2% from 2018 to 2026.
Cell therapy is a technology which relies on replacing diseased or dysfunctional cells with healthy functioning ones. Cells mainly used for such advanced therapies are stem cells, because of their ability to differentiate into the specific cells required for repairing damaged or defective tissues or cells. Moreover, cell therapy finds its application in the development of regenerative medicines which is a multidisciplinary area aimed at maintenance, improvement, or restoration of a cell, tissue, or organ function using methods mainly related to cell therapy.
Factors such as rising funding from the government as well as private organizations to support cell therapy clinical trials, growing adoption of regenerative medicine and increase in the incidence of diseases such as cancer, cardiac abnormalities are fuelling the market growth. However, the implementation of stringent government regulations regarding the use of cell therapy is anticipated to restrict the growth of the market.
By Therapy Type, Autologous therapies are going to have a significant rate during the forecast period owing to several advantages offered by them such as availability, lower risk of life-threatening complications, low rate of graft failure, low mortality rate, higher affordability and high survival rate of patients. Autologous cell therapy is a branch of regenerative medicine. It involves biologic cell-based therapies to cure various diseases related to oncology, dermatology, and neurology, among others.
The key vendors mentioned are MEDIPOST, AlloCure, Cell Medica, Kolon TissueGene, Inc., Arteriocyte Medical Systems, Forticell Bioscience, Athersys Inc., Stemedica Cell Technologies, Inc., Vericel Corporation, Baxter Healthcare Corporation, JCR Pharmaceuticals Co., Ltd., Osiris Therapeutics, Inc., Bone Therapeutics, Cellerant Therapeutics, Celgene Corporation, PHARMICELL Co., Ltd, FibrocellScinence, NuVasive, Inc, and ANTEROGEN.CO., LTD.
Key Questions Answered in this Report:
Key Topics Covered:
1 Market Synopsis
2 Research Outline
3 Market Dynamics
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Cell Therapy Market, By Therapy Type
5.2 Autologous Therapies
5.3 Allogenic Therapies
6 Global Cell Therapy Market, By Cell Type
6.2 Non-Stem Cell
6.3 Stem Cell
7 Global Cell Therapy Market, By Use & Type
8 Global Cell Therapy Market, By Therapeutic
8.2 Musculoskeletal Disorders
8.5 Autoimmune Disorders
8.6 Other Therapeutics
9 Global Cell Therapy Market, By Technology
9.2 Cell Immortalization Technology
9.3 Genome Editing Technology
9.4 Viral Vector Technology
10 Global Cell Therapy Market, By Product
10.5 Other Services
11 Global Cell Therapy Market, By Cell Source
11.2 Adipose Tissue
11.3 Umbilical Cord Blood-Derived Cells
11.4 Bone Marrow
12 Global Cell Therapy Market, By Technique
12.2 Fibroblast Cell Therapy
12.3 Cell Vaccine
12.4 Stem Cell Therapy
12.5 Chondrocyte Cell Therapy
12.6 Adoptive Cell Transfer (ACT)
13 Global Cell Therapy Market, By Application
13.2 Cardiovascular Disease (CVD)
13.4 Wound Healing
14 Global Cell Therapy Market, By End User
14.2 Regenerative Medicine Centers
14.3 Academic & Research Institutes
14.4 Hospital & Clinics
15 Global Cell Therapy Market, By Geography
15.1 North America
15.3 Asia Pacific
15.4 South America
15.5 Middle East & Africa
16 Strategic Benchmarking
17 Vendors Landscape
17.3 Cell Medica
17.4 Kolon TissueGene, Inc.
17.5 Arteriocyte Medical Systems
17.6 Forticell Bioscience
17.7 Athersys Inc.
17.8 Stemedica Cell Technologies, Inc.
17.9 Vericel Corporation
17.10 Baxter Healthcare Corporation
17.11 JCR Pharmaceuticals Co., Ltd.
By A. Rahman Ford, PNN Columnist
No group is more worthy of the revolutionary benefits of stem cell therapy than Americas military veterans. While the U.S. Department of Veterans Affairs (VA) thinks the field is in its infancy and much more research is needed before stem cells are offered as treatment, brave practitioners are stepping forward to help veterans NOW.
Dr. Joseph Kanan and his staff at the Tullahoma Chiropractic Center are providing free stem cell therapy for veterans who suffer from chronic pain. Kanan in partnership with Veterans in Pain recently performed his first pro bono procedure on a veteran named Ryan, who has severe hip pain. Stem cell injections into Ryans hip, which are not covered by insurance, normally would have cost $6,500. Ryan got them for free.
I think veterans do a lot for our country and there are very few doctors that are performing medical procedures like this, Kanan told The Tullahoma News. We were very glad to be able to do this for him.
Kanan says his Tennessee clinic performs stem cell therapy for veterans twice a month and has had good results so far. One patient was able to avoid a knee replacement and reported consistent improvement one year after the procedure. Patients can expect to experience 10 percent improvement every month for 10 months.
Veterans in Pain is a non-profit that connects military veterans with civilian physicians who provide free regenerative medicine treatments for chronic pain. VIP has provided $250,000 worth of services since 2019.
VIP founder and president Micaela Bensko is herself a stem cell therapy recipient. She spent years in a wheelchair after an accident in her driveway left her with severe spine damage that led to arachnoiditis, a chronic inflammation of spinal nerves. A friend suggested stem cell therapy, which inspired Bensko to establish VIP as a resource for veterans.
Veterans in Pain connects each veteran with a volunteer physician in their area. If one cannot be located, the cost of transportation and accommodations are covered for treatments, as they were for Ryan. Veterans associated with VIP visit schools, organizations and corporations sharing their story of recovery. Most of VIPs funding is provided by small individual donations, grants and grassroots fundraising.
According to the National Institutes of Health, nearly two-thirds of veterans report having chronic pain, with about 9% having severe pain. Chronic pain among veterans is closely associated with mental health conditions such as depression, anxiety, poor sleep and substance abuse disorders. Many veterans suffer from more than one condition.
Because of red tape and a shortage of pain management specialists at the VA, many veterans suffering from chronic pain are left devoid of proper diagnosis and treatment, causing many to self-medicate or search for answers on their own.Chronic pain can lead to substance abuse, a common and growing trend among veterans. A 2017 study found that 30% of military suicides were preceded by alcohol or drug abuse.
The dire plight of military veterans suffering from chronic pain is yet another compelling reason for the FDA to loosen its regulation of stem cell therapy. Our heroes are counting on it.
A. Rahman Ford, PhD, is a lawyer and research professional. He is a graduate of Rutgers University and the Howard University School of Law, where he served as Editor-in-Chief of the Howard Law Journal. Rahman lives with chronic inflammation in his digestive tract and is unable to eat solid food. He has received stem cell treatmentin China.
View original post here:
Non-Profit Offers Free Stem Cell Therapy to Veterans - Pain News Network
Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio – Business…
LONDON--(BUSINESS WIRE)--The global autologous cell therapy market is poised to grow by USD 1.97 billion during 2020-2024, progressing at a CAGR of almost 22% during the forecast period. Request free sample pages
Read the 120-page report with TOC on "Autologous Cell Therapy Market Analysis Report by Therapy (Autologous stem cell therapy and Autologous cellular immunotherapies), Application (Oncology, Musculoskeletal disorders, and Dermatology), Geography (North America, APAC, Europe, South America, and MEA), and the Segment Forecasts, 2020-2024".
The market is driven by the increasing demand for effective drugs for cardiac and degenerative disorders. In addition, the limitations in traditional organ transplantations are fueling the demand for stem cell therapies. All these factors are anticipated to boost the growth of the autologous cell therapy market.
The demand for effective drugs for cardiac and degenerative disorders has been increasing across the world. In addition, the discovery of possible cardiac autologous cells has enabled vendors to develop novel drugs for the treatment of various cardiac diseases. For instance, Mesoblast is developing MPC-150-IM. It is a Phase III candidate for the treatment of advanced and end-stage chronic heart failure. Similarly, Shire has been developing autologous stem cell therapies for chronic myocardial ischemia. These products are expected to be launched during the forecast period and will have a positive impact on the growth of the global autologous cell therapy market.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Major Five Autologous Cell Therapy Market Companies:
Bayer AG operates its business through segments such as Pharmaceuticals, Crop Science, Consumer Health, and Animal Health. The company offers induced pluripotent stem cells. They are developed by reprogramming mature body cells to behave like embryonic stem cells that are injected to restore diseased tissue in patients.
Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc. operates its business through an unified business segment. NurOwn is the key offering of the company. It is a cell therapy platform, which develops mesenchymal stem cells for the treatment of human diseases such as immune and inflammatory diseases.
Daiichi Sankyo Co. Ltd.
Daiichi Sankyo Co. Ltd. operates its business through segments such as Innovative Pharmaceuticals, Generic, Vaccine, and OTC Related. Heartcel is the key offering of the company. It is an immune-modulatory progenitor cell therapeutic agent, which is used for ischemic heart failure.
FUJIFILM Holdings Corp.
FUJIFILM Holdings Corp. operates its business through segments such as Imaging solutions, Healthcare and material solutions, and Document solutions. The company uses induced pluripotent stem cells to derive differentiated cells, which are used in researching various diseases and conditions.
Holostem Terapie Avanzate Srl
Holostem Terapie Avanzate Srl operates its business through an unified business segment. Holoclar is the key offering of the company. It is an advanced therapy medicinal product containing stem cells indicated to repair the cornea after injury.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
Autologous Cell Therapy Market Therapy Outlook (Revenue, USD Billion, 2020-2024)
Autologous Cell Therapy Market Application Outlook (Revenue, USD Billion, 2020-2024)
Autologous Cell Therapy Market Regional Outlook (Revenue, USD Billion, 2020-2024)
Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.
Request a free sample report
Related Reports on Healthcare Include:
Global Cancer Stem Cell Therapeutics Market Global cancer stem cell therapy market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).
Global Mantle Cell Lymphoma Therapeutics Market Global mantle cell lymphoma therapeutics market by product (combination therapy and monotherapy) and geography (Asia, Europe, North America, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results – Business Wire
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (the Company or IMV) (TSX:IMV; NASDAQ:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the fourth quarter and full year ended December 31, 2019.
We have made significant progress this past year at IMV, with multiple encouraging readouts from clinical and translational studies of our lead candidate, DPX-Survivac. Taken together, these data not only provide important validation of our platforms novel mechanism and survivin as a target antigen, but also demonstrate its ability to elicit sustained clinical activity in both solid and hematologic tumors, said Frederic Ors, Chief Executive Officer of IMV. In particular, the recent results from DeCidE1, our ongoing Phase 2 study in advanced ovarian cancer, show DPX-Survivacs potential to deliver improved outcomes over standard-of-care chemotherapy across key measures in a heavily pre-treated solid tumor population while also providing for excellent benefits and being well tolerated by patients during treatment.
Mr. Ors continued, More recently, the 2019 novel coronavirus (COVID-19) pandemic has significantly impacted businesses across all sectors and the healthcare industry is not spared. In this context, we implemented a continuity plan for our current business and clinical operations following the FDA guidance. Vaccines against infectious disease have been a core part of IMVs heritage across the DPX platform technology, and we have decided to launch the development of a DPX-based vaccine against COVID-19.
Even in these challenging times, we expect to keep a forward momentum with planned updates from ongoing Phase 2 studies. Looking ahead, as we hope to accumulate proof-of-concept in multiple hard-to-treat indications, we plan to engage with the U.S. Food and Drug Administration (FDA) on the design of potential pivotal trials in support of an accelerated pathway for DPX-Survivac in advanced ovarian cancer and r/r DLBCL."
Development of the DPX-COVID-19 vaccine candidate
On Wednesday, March 18, 2020, IMV announced in a press release plans to develop of a DPX-based vaccine candidate for COVID-19 in collaboration with experts in the field. Earlier today, we announced an update on our progress:
IMV will continue to provide updates on the development of DPX-COVID-19, and is working on a dedicated DPX-COVID-19 page on its website.
DPX-Survivac Clinical Program Updates
Phase 2 DeCidE1 Study in Advanced Recurrent Ovarian Cancer
DeCidE1 is a Phase 2 multicenter, randomized, open-label study to evaluate the safety and efficacy of DPX-Survivac with intermittent low dose cyclophosphamide (CPA). This phase 2 arm enrolled 22 patients with recurrent, advanced platinum-sensitive and/or resistant ovarian cancer.
In February 2020, IMV reported interim data from this study, demonstrating amongst others:
At the time of the data cutoff, six (31%) patients remained on therapy. Five (26%) of these patients were still on treatment at > 6 months. Additional data available here.
Phase 2 SPiReL Study in r/r DLBCL
SPiReL is an investigator-initiated Phase 2 study evaluating DPX-Survivac and CPA in combination with Keytruda (pembrolizumab) in r/r DLBCL.
In December 2019, updated clinical results were reported in a poster presentation at the American Society of Hematology (ASH) annual meeting in Orlando, FL. Highlights of the data included:
The study remains ongoing, with preliminary topline results expected in 2020.
Phase 2 Basket Trial in Multiple Advanced Metastatic Solid Tumors
The Basket Trial is an open label, multi-center Phase 2 study, evaluating the safety and efficacy of DPX-Survivac and CPA in combination with Keytruda across five cohorts of patients with bladder cancer, liver cancer (hepatocellular carcinoma), ovarian cancer (with and without CPA), NSCLC and tumors shown to be positive for the microsatellite instability high (MSI-H) biomarker.
As of March 24, 2020, a total of 82 patients were enrolled across all five indications out of a maximum target number of 184 patients.
In the context of the COVID-19 pandemic, IMV expects to report preliminary topline clinical results on several of the solid tumor indications later in 2020.
Clinical Translational Studies
In November 2019, IMV presented translational data from the DeCidE1 clinical study at the 34th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC) in National Harbor, MD. The data validate DPX-Survivacs underlying mechanism of action and are available here.
In February 2020, Dr. Oliver Dorigo, MD, Ph.D. presented, on behalf of IMV, translational data supporting DPX-Survivacs mechanism of action at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, FL. The data included samples collected from three Phase 1 and/or Phase 2 studies evaluating DPX-Survivac alone or in a combination regimen in patients with advanced, platinum-sensitive or resistant ovarian cancer and are available here.
Additionally, the team continues to monitor updated institutional, regional and national guidance to fully comply with applicable guidelines as they are issued. It is noted that some clinical sites have paused or slowed enrollment in clinical trials, while other sites, less impacted, are continuing activities as planned. The overall enrollment rate may decrease, but clinical activities are continuing, and patients are encouraged to comply with directives from public health officials and, subject to such compliance, to attend visits as planned or to discuss alternatives with their physician.
The current activities performed at central labs to assess the eligibility of patients and the management of clinical samples is not impacted, and IMV is working with the vendors to ensure continuity of activities. Finally, drug supply is not expected to be impacted at this time. As added precaution, IMV is working on a contingency plan to ensure proper provisioning of drugs to all clinical sites in the event of future transportation or other constraints.
Over the course of upcoming quarters, the Company expects to deliver the following milestones:
Overview of Year-End 2019 Financial Results
Research and development expenses increased by $6,044,000 for the year ended December 31, 2019, compared to 2018. These increases are mainly due to expenses related to the ongoing basket trial, pre-clinical development of DPX-SurMAGE for bladder cancer and personnel costs due to an increase in headcount. The increase is also attributable to manufacturing activities to support the increased clinical activity, which included purchasing raw materials and contract manufacturing organization costs.
General and administrative expenses increased by $897,000 for the year ended December 31, 2019 compared to 2018. This increase is mainly due to personnel costs as a result of increased head count, investor relations activities, a full year of increased insurance premiums and regulatory fees following the Nasdaq listing in mid-2018, and a full year of increased rent, lease interest accretion, and utilities following the move to its new Dartmouth facility in mid-2018.
The net loss and comprehensive loss of $27,365,000 ($0.55 per share) the year ended December 31, 2019 was $5,430,000 higher than the net loss and comprehensive loss for the year ended December 31, 2018.
At December 31, 2019, the Corporation had cash and cash equivalents of $14,066,000 and working capital of $13,199,000, compared with $14,895,000 and $12,247,000, respectively at December 31, 2018. For the year ended December 31, 2019, IMV's cash burn rate, defined as net loss for the period adjusted for operations not involving cash (interest on lease obligation, depreciation, accretion of long-term debt, stock-based compensation and DSU compensation), was $25.5 million. IMV expects research and development expenditures to increase over time due to the continuing development of product candidates and other clinical, preclinical, and regulatory activities.
As of March 30, 2020, the number of issued and outstanding common shares was 51,028,180 and a total of 1,959,452 stock options and deferred share units were outstanding.
The Corporation's audited annual consolidated results of operations, financial condition and cash flows for the year ended December 31, 2019 and the related management's discussion and analysis (MD&A) are available on SEDAR at http://www.sedar.com and on EDGAR at http://www.sec.gov/edgar.
Conference Call and Webcast Information
Management will host conference call and webcast tomorrow, March 31, 2020 at 8:00 a.m. ET. Financial analysts are invited to join the conference call by dialing (866) 211-3204 (U.S. and Canada) or (647) 689-6600 (international) using the conference ID# 7482187 Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations.
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies and vaccines based on the Companys proprietary drug delivery platform (DPX). This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMVs lead candidate, DPX-Survivac, is a T cell-targeted immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac targeted therapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at http://www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the Companys intention to develop a DPX-based vaccine candidate against COVID-19, the Companys belief that the DPX-based platform creates the opportunity for accelerated development and rapid, large-scale production of a COVID-19 vaccine, the Companys belief in the potential efficacy of its DPX-based vaccine against COVID-19, the Companys belief in the benefits of the third-party research and studies in related coronavirus and SARS studies and third-party sequencing data and their applicability to the Companys DPX platform and a DPX platform related vaccine, the expected milestone completion dates and the Companys anticipated results and expected timing of such results from its DPX cancer and infectious disease studies. Such statements should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks and uncertainties affecting the Company and its products. The Company assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties and those risks and uncertainties include, but are not limited to, the Companys ability to develop a DPX-based vaccine candidate against the COVID-19 through the successful and timely completion of clinical trials and studies, the receipt of all regulatory approvals by the Company to commence and then continue clinical studies, and, if successful, the commercialization of its proposed vaccine candidate related to COVID-19, the Companys ability to raise sufficient capital to fund such clinical trials and studies and the production of any COVID-19 vaccine, the ultimate applicability of any third-party research and studies in related coronavirus and SARS studies and sequencing, the Companys ability to enter into agreements with the proposed lead investigators to assist in the clinical development on its vaccine candidate related to COVID-19, the Companys ability to collaborate with governmental authorities with respect to such clinical development, the coverage and applicability of the Companys intellectual property rights to any vaccine candidate related to COVID-19, the ability of the Company to manufacture any vaccine candidate related to COVID-19 rapidly and at scale and other risks detailed from time to time in the Companys ongoing filings and in its annual information form filed with the Canadian regulatory authorities on SEDAR as http://www.sedar.com and with the United States Securities and Exchange Commission on EDGAR at http://www.sec.gov/edgar. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Companys continuous disclosure documents which are available on SEDAR and on EDGAR.
Consolidated Statements of Loss and Comprehensive Loss
(In thousands of Canadian dollars, except shares and per share amounts)
Research and development
General and administrative
Total operating expenses
Net loss and comprehensive loss
Basic and diluted loss per share
Weighted-average shares outstanding
Consolidated Statements of Financial Position
(In thousands of Canadian dollars, except shares and per share amounts)
The Expanding Treatment Landscape of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma – Pharmacy Times
The Expanding Treatment Landscape of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Dr. Harnicar started the session with an overview of the second most common type of NHL, follicular lymphoma (FL). This slow growing cancer (median overall survival is 20 years) increases in incidence with age, affecting men and women equally. Roughly 20% of patients need treatment within 3 years of diagnosis. He discussed prognostic tools used to predict which patients were likely to have early disease progression and poor long-term outcomes.
FL can be insidious and relentless; patients can experience multiple relapses requiring treatment. With each relapse, the duration of response tends to shorten. For patients with early relapses (progression fewer than 2 years after diagnosis), the standard therapy is not well defined and may include stem cell transplant; phosphatidylinositol 3-kinase (PI3K) inhibitors duvelisib, copanlisib, or idelalisib; or lenalidomide plus rituximab. Patients with late relapses or multiple relapses may receive chemoimmunotherapy with rituximab maintenance, bendamustine and obinutuzumab with obinutuzumab maintenance, PI3K inhibitors, or lenalidomide with rituximab.
Next, Dr. Harnicar covered the rare, aggressive mantle cell lymphoma. Risk increases with age, white race, and male sex. One of the most important prognostic markers is the presence of TP53 mutations and overexpression. Second-line therapy options are dependent on short versus extended response to firstline therapy. Multiple options exist and oral therapies, including Brutons tyrosine kinase (BTK) inhibitors (eg, acalabrutinib, ibrutinib, or zanubrutinib), venetoclax, or lenalidomide often in combination with anti-CD20 monoclonal antibodies are commonly chosen.
Dr. Auten followed with information on pharmacists roles now that these NHLs can be treated with small molecule inhibitors and various combinations of oral and infusion agents. She focused on management of patients receiving BTK, PI3K, and BCL2 inhibitors.
A primary concern with ibrutinib is the number of potential concomitant medications metabolized by CYP3A and drug interactions. Clinicians must be cognizant of steps to take to minimize downstream effects of interactions. Ibrutinib can cause bleeding, as can acalabrutinib, so it is critical to ensure that patients stop taking supplements associated with bleeding, discontinue aspirin, and use a direct oral anticoagulant rather than warfarin if anticoagulation is needed. Monitoring for cardiac adverse effects (eg, arrhythmias, hypertension) is an ongoing need and is seen with a higher incidence in patients receiving ibrutinib.
Class toxicities associated with the PI3K inhibitors include immune-related effects (eg, hepatotoxicity, diarrhea/colitis that may require systemic steroids, and pneumonitis), hypertension, hyperglycemia, dermatologic manifestations, hepatotoxicity, and infection. Dr. Auten discussed when to interrupt therapy with the PI3K inhibitors due to adverse effects.
Venetoclax is a drug that must be titrated upward at initiation due to risk of tumor lysis syndrome and patients must be carefully monitored based on risk. Venetoclax has also been associated with myelosuppression, and administering a granulocyte colony-stimulating factor and holding or reducing the dose is prudent.
Dr. Auten reiterated steps that pharmacists need to take to ensure patient safety, while emphasizing infection prophylaxis. She concluded by sharing evidence to support that clinical and specialty pharmacists are uniquely positioned to improve communication, patient activation, and shared decision making with this patient population and their health care providers.
Ever since the novel coronavirus, or COVID-19, was first reported in China's Wuhan city, the virus has spread to more than 196 countries and territories around the world with393,284 confirmed cases and17,161 deaths so far. In India, the maximum number of cases has been reported in the state of Maharashtra.The number of coronavirus cases in the country has risen to 519, with 10 deaths.
It is the need of the hour to find a solution for coronavirus.
Clinical trials in China are already testing the efficacy of stem cell therapies for COVID-19. Arecent clinical trialwith seven COVID-19 patients showed that a stem cell product improved patient outcome. According to research published in the peer-reviewed journalAging and Disease,mesenchymal stem cell (MSC) therapy could be effective in treating COVID-19.
Coronaviruses (CoV) belong to a large family of viruses leading to respiratory illnesses, such as common coldto more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute RespiratorySyndrome (SARS-CoV).
Earlier this year, a new strain of coronavirus was discovered, which was not previously identified in humanbeings, also known as the novel coronavirus (nCov). The symptoms of the infection are respiratory issues, fever, cough, shortness of breath, and breathingdifficulties. More severe cases of COVID-19 can cause pneumonia, severe acute respiratory syndrome, and kidneyfailure.
In recent years, scientific research hasshown that MSCs have properties that maymake them very useful to repair damaged tissues in the patients respiratory system and promotefaster healing and recovery.Umbilical cord tissueis particularly rich inthese cells, which is why many parents arechoosing to store them at birth.
MSCs can reduce the overproduction of immune cells caused by a reaction to the virus and reduce excessive levels of inflammatory substances, thus regulating the immune system.
Currently, many vaccines or drugs are being tested to deal with coronavirus. There is widespread fear and phobia among the population. Why not use your own defence system rather than searching for drugs to tackle the virus?
MSCs are multi-potent cells that have been widely used for tissue regeneration and immunomodulation, and can be a potential solution. The infusion of autologous and allogenic MSCs has been proven safe and effective in tissue repair and disease modulation. MSCs have anti-inflammatory, antimicrobial properties; therefore, they have the potential to control inflammatory conditions, possibly viral diseases, and may reduce mortality.
Another interesting therapeutic avenue is immunotherapy. Natural killer (NK) cells, a component of our innate immune system, play an important role in tackling malignancies as well as virally infected cells. These cells serve to contain viral infections while the adaptive immune response is generating antigen-specific cytotoxic T cells that can clear the infection. Thus, NK cell therapy can be safe and effective in the management of COVID-19.
We need to ensure control of person-to-person transmission of the infection. Therefore, stringent isolation/quarantine measures are important until complete recovery of an infected individual.
(Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the views of YourStory.)
How has the coronavirus outbreak disrupted your life? And how are you dealing with it? Write to us or send us a video with subject line 'Coronavirus Disruption' to email@example.com
Originally posted here:
Can cell-based therapy be helpful in tackling coronavirus? - YourStory